A line of products used for the temporary relief of burning and irritation caused by dry eye was shown to increased meibomian gland function from baseline compared with warm compresses.
Boston—Symptoms of lipid-deficient evaporative dry eye disease can be alleviated with therapeutics that increase the number of meibomian glands yielding liquid secretion.
A line of products (Systane Family of Products, Alcon Laboratories) used for the temporary relief of burning and irritation caused by dry eye increased meibomian gland function from baseline compared with warm compresses with or without saline—the standard of care.
“Meibomian gland dysfunction (MGD) is one of the leading causes of dry eye disease, which is characterized by decreased liquid secretion or a decreased number of meibomian glands yielding liquid secretion and altered gland anatomy,” said Victor Finnemore, OD, partner and clinical researcher at Korb and Associates, Boston.
Dr. Korb and colleagues conducted a 3-month, single-center, open-label, investigator-masked, prospective evaluation of patients diagnosed with lipid-deficient evaporative dry eye and six or fewer functioning meibomian glands during screening. Patients completed screening at baseline and examinations at 1, 2, and 3 months of treatment.
The 3-month study included random assignment to either the Systane products (Lid Wipes once daily, Systane Balance eye drops four times daily, and two oral vitamins once daily) or the application of warm wet compresses to both eyelids for 8 minutes once daily, according to Dr. Finnemore.